Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Leiomyosarcoma 2Neoplasms 1

Interventions

Doxorubicin 5Dacarbazine 5Trabectedin 3belinostat 2PTC596 2toripalimab 1soblidotin 1rucaparib 1ridaforolimus 1reolysin 1pembrolizumab 1pazopanib 1olaratumab 1futibatinib 1cixutumumab 1cemiplimab 1anlotinib 1Tablets 1TTI-621 1Rosuvastatin Calcium 1PM 01183 1Midazolam 1Injections 1Imatinib Mesylate 1Ifosfamide 1Fluorouracil 1Erlotinib Hydrochloride 1Docetaxel 1Digoxin 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Leiomyosarcoma × PTC596 × Clear all
NCT05269355 2025-06-13

SUNRISELMS

PTC Therapeutics

Phase 2/3 Terminated
359 enrolled 15 charts
Sarcoma

Leiomyosarcoma

NCT03761095 2024-03-15

A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

PTC Therapeutics

Phase 1 Completed
41 enrolled
Sarcoma

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡